Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retinoid therapy for psoriasis.

Paul S Yamauchi1, Dalia Rizk, Nicholas J Lowe

  • 1Clinical Research Specialists, 2001 Santa Monica Boulevard, Suite 490W, Santa Monica, CA 90404, USA.

Dermatologic Clinics
|September 29, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.

Advances in therapy·2026
Same author

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.

JAMA dermatology·2025
Same author

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.

Journal of the American Academy of Dermatology·2024
Same author

Predatory Conferences and Journals in Dermatology Are Black Widow Parties.

Skinmed·2024
Same author

Management of scrotal pruritus with topical roflumilast 0.3% once daily treatment.

JAAD case reports·2024
Same author

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.

Journal of the American Academy of Dermatology·2024

Acitretin is the primary systemic retinoid for psoriasis treatment, with topical tazarotene and combination therapies also detailed. The review covers new retinoid analogues and discusses associated toxicities.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Retinoids are a class of drugs used in dermatology.

Purpose of the Study:

  • To review the use of acitretin, a systemic retinoid, for psoriasis treatment.
  • To discuss topical retinoids, combination therapies, and emerging retinoid analogues.
  • To outline potential toxicities and adverse effects of retinoid therapy.

Main Methods:

  • Literature review of systemic and topical retinoid therapies for psoriasis.
  • Discussion of combination treatments including phototherapy.
  • Overview of ongoing clinical investigations for new retinoid analogues.

Main Results:

Related Experiment Videos

  • Acitretin is the sole approved systemic retinoid for psoriasis.
  • Topical tazarotene offers another retinoid treatment option.
  • Combination therapies enhance retinoid efficacy for psoriasis.

    • Conclusions:

    • Acitretin and topical tazarotene are key retinoids in psoriasis management.
    • Combination strategies and new analogues show promise.
    • Careful monitoring for retinoid toxicities is essential.